Sam Daneshvari, MD
Nephrology · Glendale, CANPI 1851496145
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 262 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$915
- Otsuka America Pharmaceutical, Inc.$567
- Mallinckrodt Hospital Products Inc.$412
- Aurinia Pharma U.S., Inc.$400
- Akebia Therapeutics Inc$344
- plus $2K from 20 others
Across 216 payments — averaging $5179.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$898K
- Akebia Therapeutics Inc$170K
- Merck$40K
- Alnylam Pharmaceuticals Inc.$11K
What the payments were for
- Food & beverage$5,82795%
- Education$2795%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 66 | $1,332 |
| Amgen(2 entities) | 39 | $915 |
| Otsuka America Pharmaceutical, Inc. | 31 | $567 |
| Mallinckrodt Hospital Products Inc. | 15 | $412 |
| Aurinia Pharma U.S., Inc. | 11 | $400 |
| Akebia Therapeutics Inc | 17 | $344 |
| GSK | 11 | $281 |
| Bayer | 9 | $267 |
| Vifor Pharma, Inc. | 11 | $228 |
| Fresenius USA Marketing, Inc. | 10 | $161 |
| Nuwellis, Inc. | 2 | $158 |
| Travere Therapeutics, Inc. | 2 | $143 |
| Johnson & Johnson | 2 | $139 |
| Novartis | 6 | $121 |
| Novo Nordisk | 6 | $119 |
| OPKO Pharmaceuticals, LLC | 7 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Boehringer Ingelheim | 4 | $81 |
| AbbVie(2 entities) | 3 | $69 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Sanofi | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,106 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 127 | $86,196 |
| Tolvaptan | 17 | $70,686 |
| ProsolParenteral Amino Acid 20% No.1 | 175 | $26,521 |
| ProcritEpoetin Alfa | 13 | $19,419 |
| Sevelamer Hcl | 13 | $17,515 |
| KerendiaFinerenone | 21 | $14,823 |
| DapagliflozinDapagliflozin Propanediol | 17 | $8,857 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $7,472 |
| JardianceEmpagliflozin | 13 | $6,282 |
| Febuxostat | 60 | $4,633 |
| Calcium Acetate | 40 | $2,692 |
| Clonidine | 39 | $1,987 |
| Calcitriol | 62 | $1,656 |
| Verapamil SrVerapamil Hcl | 14 | $1,406 |
| Hydralazine Hcl | 144 | $943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,332 | $93,669144 claims |
| Johnson & JohnsonProcrit | $139 | $19,41913 claims |
| BayerKerendia | $267 | $14,82321 claims |
| Boehringer IngelheimJardiance | $81 | $6,28213 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $23 | $33430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Glendale
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.